ATE397669T1 - Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase - Google Patents

Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase

Info

Publication number
ATE397669T1
ATE397669T1 AT03761600T AT03761600T ATE397669T1 AT E397669 T1 ATE397669 T1 AT E397669T1 AT 03761600 T AT03761600 T AT 03761600T AT 03761600 T AT03761600 T AT 03761600T AT E397669 T1 ATE397669 T1 AT E397669T1
Authority
AT
Austria
Prior art keywords
drug
hiv
drug resistance
phenotypical
reverse transcriptase
Prior art date
Application number
AT03761600T
Other languages
English (en)
Inventor
Hilde Azijn
Bethune Marie-Pierre T M M De
Johan Vingerhoets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE397669T1 publication Critical patent/ATE397669T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03761600T 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase ATE397669T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39300502P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
ATE397669T1 true ATE397669T1 (de) 2008-06-15

Family

ID=30000959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761600T ATE397669T1 (de) 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase

Country Status (7)

Country Link
US (2) US7473524B2 (de)
EP (1) EP1522039B1 (de)
AT (1) ATE397669T1 (de)
AU (1) AU2003251732B2 (de)
CA (1) CA2490764C (de)
DE (1) DE60321466D1 (de)
WO (1) WO2004003223A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246859T3 (es) * 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
EP1356082A2 (de) * 2000-10-20 2003-10-29 Virco Bvba Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase
DE60321466D1 (de) * 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
EP1520247B1 (de) * 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
CA2684061A1 (en) * 2007-04-10 2008-10-16 Emory University Novel hiv-1 reverse transcriptase codon deletion and its use in the management and treatment of hiv infections

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327742A (en) 1885-10-06 Machine for making nuts
DE3235565A1 (de) 1982-09-25 1984-03-29 Boehringer Ingelheim KG, 6507 Ingelheim Piperidinderivate, ihre herstellung und verwendung
JPS5974341A (ja) 1982-10-19 1984-04-26 Nissan Motor Co Ltd 車両用アクセル制御装置
GB2229340B (en) 1989-03-17 1994-02-09 Technophone Ltd Radio telephone system
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
AU4248593A (en) * 1992-05-14 1993-12-13 Mark Holodniy Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
BR9704637A (pt) 1996-01-26 1998-06-09 Innogenetics Nv Processo para deteção de mutações induzidas por droga no gene de transcrição reversa
KR100495690B1 (ko) * 1996-01-26 2005-11-08 비르코 비브이비에이 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법
EP0852626B1 (de) 1996-01-29 2002-04-03 Virologic, Inc. Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
NZ508834A (en) 1998-05-26 2004-06-25 Virologic Inc Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
AU4673399A (en) 1998-05-28 1999-12-13 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
CA2872424C (en) 1998-06-23 2017-03-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Bisfuran derivatives useful in preventing the emergence of multidrug resistant hiv strains and treatment of hiv
BR9912209A (pt) 1998-06-24 2002-11-05 Virologic Inc Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids
AU762811B2 (en) 1998-06-24 2003-07-03 Innogenetics N.V. Method for detection of drug-selected mutations in the HIV protease gene
ES2246859T3 (es) * 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
AU5758200A (en) * 1999-06-22 2001-01-09 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU5883300A (en) 1999-06-23 2001-01-09 Penn State Research Foundation, The Compositions and methods for the quantification of sterol biosynthetic flux
ATE526423T1 (de) * 2000-04-18 2011-10-15 Virco Bvba Verfahren zum messen des medikamentenwiderstands gegen hcv
AU2001256318B8 (en) 2000-04-20 2007-03-22 Virco Bvba Method for mutation detection in HIV using pol sequencing
EP1352356B1 (de) 2000-06-08 2009-10-14 Virco Bvba Verfahren um die resistenz gegen ein therapeutisches agenz vorherzusagen unter verwendung neuronaler netze
US7058616B1 (en) * 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
WO2002022076A2 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
EP1356082A2 (de) * 2000-10-20 2003-10-29 Virco Bvba Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase
JP4264256B2 (ja) 2000-10-20 2009-05-13 ビルコ・ビーブイビーエイ 治療に対する耐性を予測するための生物学的カット−オフ値の確立
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
CA2429073A1 (fr) 2000-11-10 2002-05-16 Bioalliance Pharma Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
US7659404B2 (en) 2001-02-14 2010-02-09 Tibotec Pharmaceuticals Ltd. Broad spectrum 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors
EP1319738A1 (de) * 2001-12-17 2003-06-18 Atofina Research S.A. Modifizierte Polyolefinfasern
EP1520247B1 (de) * 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
DE60321466D1 (de) * 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
CA2497979A1 (en) 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives
EP1605064A1 (de) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind.

Also Published As

Publication number Publication date
WO2004003223A3 (en) 2005-02-17
WO2004003223A2 (en) 2004-01-08
DE60321466D1 (de) 2008-07-17
EP1522039B1 (de) 2008-06-04
AU2003251732A1 (en) 2004-01-19
US20050239053A1 (en) 2005-10-27
US8076062B2 (en) 2011-12-13
US20090061420A1 (en) 2009-03-05
AU2003251732B2 (en) 2008-09-18
CA2490764C (en) 2011-11-22
CA2490764A1 (en) 2004-01-08
EP1522039A2 (de) 2005-04-13
US7473524B2 (en) 2009-01-06

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Hellard et al. Hepatitis C transmission and treatment as prevention–The role of the injecting network
Lythgoe et al. Shared SARS-CoV-2 diversity suggests localised transmission of minority variants
ATE432506T1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
Jabara et al. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection
ATE397669T1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse- transkriptase
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
Bartlett et al. HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection
Getaneh et al. Survival and Predictors of Mortality among Adults Initiating Highly Active Antiretroviral Therapy in Ethiopia: A Retrospective Cohort Study (2007‐2019)
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
BR9911600A (pt) Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Zhao et al. Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
EP1407042A4 (de) Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids
Bartlett et al. A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015
Lasek-Nesselquist et al. A statewide analysis of SARS-CoV-2 transmission in New York
Metsky et al. Capturing diverse microbial sequence with comprehensive and scalable probe design
Wirden et al. Benefits of HIV‐1 transmission cluster surveillance: a French retrospective observational study of the molecular and epidemiological co‐evolution of recent circulating recombinant forms 94 and 132
KR200208239Y1 (ko) 특정인의 ｄｎａ구조를 형상화한 팔찌
AU2014347768A1 (en) HCV genotyping algorithm
Zhao et al. Directional predictions of HIV transmission with optimised genomics in cohorts of serodiscordant couples
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007
Minteer et al. A DNAmCULTURE Epigenetic Fingerprint Recapitulates Physiological Aging

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1522039

Country of ref document: EP